• Coloplast posted Q3 2025/26 EBIT of DKK 1.93 billion, up 1% from a year earlier; EBIT margin narrowed 2 percentage points to 26%.
• For the first nine months, EBIT fell 2% to DKK 5.6 billion; EBIT margin slipped 1 percentage point to 26%.
• Net profit before special items rose to DKK 4.29 billion, helped by lower net financial items from exchange-rate adjustment gains.
• Management cited strong momentum in Chronic Care ex-China and Interventional Urology, while Biologics sales declined 6% on a reimbursement change.
• Full-year guidance stayed unchanged, with organic revenue growth seen at 5%-6% and EBIT growth in constant currencies around 5%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coloplast A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180130OMX_____CNEWS_EN_GNW1001258066_en) on August 18, 2026, and is solely responsible for the information contained therein.